The EX-PRESS^® Glaucoma Filtration Device is indicated for open-angle glaucoma patients for whom medication and other conventional surgical treatments have failed, including patients who have previously undergone unsuccessful trabeculectomies.

Clinical studies have shown that the EX-PRESS^® Glaucoma Filtration Device's implantation procedure effectively maintains steady pressure in the anterior chamber during surgery, and the device's post-op IOP-lowering capability is comparable to the trabeculectomy.¹ EX-PRESS^® Glaucoma Filtration Device patients also enjoy a decrease in the need for IOP-lowering medication in the long-term, compared with trabeculectomy patients.²

The Lumenal Control of the EX-PRESS^® Glaucoma Filtration Device was developed through extensive research and realized through precise six-point engineering. By filtering aqueous humor flow from the anterior chamber into a subconjunctival bleb through a standardized lumen, the EX-PRESS^® Glaucoma Filtration Device yields predictable, repeatable results. Learn more about Lumenal Control.

Not only do EX-PRESS^® Glaucoma Filtration device patients experience lower rates of hypotony and choroidal effusion versus trabeculectomy patients,1 but they also average faster recovery rates and fewer post-op visits.³ Read more about the EX-PRESS^® Glaucoma Device safety profile.

Corneal decompensation is not an adverse event generally associated with the EX-PRESS^® Glaucoma Filtration Device.

Like the trabeculectomy, the EX-PRESS^® Glaucoma Filtration Device diverts aqueous humor flow from the anterior chamber to a bleb in the subconjunctival space. Where the methods differ is in the EX-PRESS^® Glaucoma Filtration Device's standardized lumen — which maintains uniform aqueous humor outflow — and the dual inlet, which allows for continued drainage even in the event of blockage of the tip.

Yes. The device is made of surgical-grade stainless steel, a biocompatible material that has been in use in ORs for more than 30 years. The device has been shown to produce minimal inflammation and scarring.⁴

The EX-PRESS^® Glaucoma Filtration Device labeling states MRI of the head is permitted, though not recommended, in the first two weeks post implantation. ⁵

Use of the EX-PRESS^® Glaucoma Filtration Device is covered by Medicare, as well as most commercial payers.